Shen Jian, Yang Jiping, Heyse Winfried, Schweitzer Harald, Nagel Norbert, Andert Doris, Zhu Chengyue, Morrison Vincent, Nemeth Gregory A, Chen Teng-Man, Zhao Zhicheng, Ayers Timothy A, Choi Yong-Mi
Sanofi, 1041 Route 202-206, Bridgewater, NJ 08807, United States.
Sanofi, Industriepark Hoechst Bldg., D-65926 Frankfurt, Germany.
J Pharm Anal. 2014 Jun;4(3):197-204. doi: 10.1016/j.jpha.2013.10.001. Epub 2013 Nov 26.
Otamixaban is a potent (Ki=0.5 nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric characterization has been accomplished using vibrational circular dichroism (VCD) spectroscopy. Selected by a spectrum similarity index, the calculated spectra of several higher energy conformers were found to match well with the observed spectra. The characteristic IR bands of these conformers were also identified and attributed to the solvation effect. Combined with both the single crystal x-ray diffraction results for an intermediate and the proton NMR study, the absolute configuration of Otamixaban is unambiguously determined to be (,).
奥他米班是一种强效(Ki = 0.5 nM)的Xa因子抑制剂,赛诺菲公司目前正处于急性冠脉综合征治疗的后期临床开发阶段。由于难以获得合适的奥他米班晶体,因此利用振动圆二色光谱(VCD)完成了所需的对映体表征。通过光谱相似性指数进行筛选,发现几个高能构象体的计算光谱与观测光谱匹配良好。还确定了这些构象体的特征红外波段,并归因于溶剂化效应。结合中间体的单晶X射线衍射结果和质子核磁共振研究,明确确定奥他米班的绝对构型为(,)。